Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Retail

Fevertree Drinks shares sparkle on 'strong' first half

The tonic, ginger beer and lemonade maker also reiterated its full-year guidance from July, saying revenue will be between £355mln and £365mln, with EBITDA at £37.5mln to £45mln

Fevertree Drinks (AIM:FEVR) delivered a “strong” first half with consumer demand remaining healthy, particularly across Southern Europe and America.

The premium drink mixers company saw revenue growth of 14% to £160.9mln in the six months to 30 June, despite gross profit easing 4% to £60.1mln.

"Fevertree has delivered a robust revenue performance in the first half of 2022, with a particularly strong performance in Europe as the on-trade recovered,” Tim Warrillow, chief executive, commented.

However, pricing actions in its more established markets and improvements in sales only partially mitigated ongoing industry-wide inflation and rising cost headwinds, resulting in a 6.7 percentage point reduction in gross margin to 37.4%.

The tonic, ginger beer and lemonade maker, to name a few, claimed it remained the "clear market leader" in the UK, with the region accounting for 33% of total group revenue.

Fevertree also upped its interim dividend 2% year-on-year to 5.63p despite earnings per share sinking 31% to 12.1p.

The company ended the period with a “strong balance sheet,” underpinned by cash of £100mln and the payment of the £50mln special dividend announced in March.

It reiterated its full-year guidance from July, saying revenue will be between £355mln and £365mln, with EBITDA at £37.5mln to £45mln.

Fevertree had a strong start to the second half of the year, with August a standout month in the company’s history.

“Demand has been strong in the US and we have continued to increase our availability on shelf, enabling us to deliver a record month in August, a fantastic achievement by the team,” Warrillow added.

Its shares fizzed 12% higher in early morning trading to change hands at 1,064p.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK